Microbiological approaches are faster and more advanced than ever before – so why on earth isn’t the pharma industry using them?

When seeking to measure quality across an organization, what is the right approach?

Clinical development is outmoded; we are witnessing serious attrition in cancer R&D. Perhaps it’s time to live and die by the mantra: “no biomarker, no trial”.

The EMA fights to reinstate its former executive director – and the FDA’s new leader is still unconfirmed

As the industry makes its video game debut, the big question is: will you prioritize patients over profit? Here’s our big review.

Researchers redesign existing drugs to be more biodegradable and environmentally friendly.

A digital pill submitted for regulatory approval tells caregivers if you’ve taken your medicine

Genome mining hunts for bacteria micro-chemists that could help develop innovative drugs.

Expedited regulatory approvals bring medicines to market faster – but are they the right drugs?

Mislabeled, substandard or falsified medicines are the perfect opportunity for criminals looking for low risks and high rewards.